Intervention evaluation
nephrolithiasis, lower urinary tract symptoms, pain
NEPHROLITHIASIS, ADVERSE EFFECTS
In group A (silodosin group), individuals received a daily dose of 8 mg of silodosin for 1 week prior to surgery. This dosage was determined based on the highest permitted dose for individuals with lower urinary tract symptoms. Patients who underwent the procedure while experiencing acute, unbearable pain despite medication were excluded from the study. Following admission and within 10 days of hospitalization, all patients received silodosin tablets for a week, underwent preoperative examination and surgery and were followed up. A prophylactic antibiotic was administered prior to the surgical procedure. The researcher assessed the adverse effects of silodosin and patient adherence to medication by counting the pills on the day of admission. In group B (Placebo/control group), patients underwent f-URS with daily preoperative intake of placebo tablets.During the study period, a single expert surgeon (MSC), who had performed over 500 procedures for nephrolithiasis and conducted retrograde intrarenal surgery (RIRS) using an f-URS with a distal-end outer diameter of 8.5 Fr, performed the procedure on all patients.